Business Context and Reporting Period
Company: Oramed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 21, 2023
Event: Entry into a Material Definitive Agreement and Termination of a Prior Agreement.
On September 21, 2023, Oramed Pharmaceuticals Inc. (the "Company") consummated a transaction with Scilex Holding Company ("Scilex") following Scilex's emergence as the winning bidder in an auction related to Sorrento Therapeutics, Inc.'s ("Sorrento") Chapter 11 bankruptcy proceedings. This transaction replaced a previously negotiated agreement with Sorrento.
Key Financial Metrics and Transaction Terms
The filing details a complex financial restructuring rather than standard operating results. Key financial components include:
- Debt Instrument: Scilex issued a Senior Secured Promissory Note to the Company with a principal amount of $101,875,000.
- Interest Rate: Term SOFR plus 8.5% (with a 4.0% floor), payable in-kind (PIK).
- Maturity: March 21, 2025, subject to mandatory prepayments.
- Equity/Warrant Consideration:
- Closing Penny Warrant: To purchase 4,500,000 shares of Scilex Common Stock at $0.01/share.
- Subsequent Penny Warrants: To purchase 8,500,000 shares of Scilex Common Stock at $0.01/share (vesting quarterly).
- Transferred Warrants: 4,000,000 shares of Scilex Common Stock at $11.50/share (transferred from Sorrento).
- Expense Reimbursement: Scilex agreed to reimburse up to $2,910,000 in legal and advisor costs ($1,910,000 paid in cash; $1,000,000 added to Note principal).
- Liquidity Covenants: Scilex must maintain minimum liquidity of $1 million (first 60 days), $3 million (days 61-180), and $5 million thereafter.
Material Changes Versus Prior Period
Termination of Sorrento Agreement: The Company and Sorrento mutually terminated the "Sorrento SPA" (originally dated August 7, 2023) with no termination penalties incurred. This ended the Company's prior agreement to acquire equity securities from Sorrento for $105 million.
Shift in Counterparty: The transaction shifted from an acquisition of Sorrento assets to a debt and warrant investment in Scilex. The Company assumed the role of a senior secured lender to Scilex rather than an equity acquirer of Sorrento.
Assumption of DIP Loan: Scilex assumed Sorrento's outstanding obligations under the $100 million Senior DIP Loan Facility previously provided by the Company. This assumption served as partial consideration for the new Note and warrants.
Outlook, Risks, and Management Commentary
Management Commentary: The Company secured a senior secured position in Scilex with significant equity upside through warrants. The transaction includes a Board Observer right for the Company until the Note is repaid.
Risks and Contingencies:
- Default Provisions: Upon an event of default, the Note bears interest at Term SOFR plus 15.0% (PIK) and requires repayment at 125% of the principal amount.
- Exit Fee: If the Note is not repaid in full by March 21, 2024, an exit fee of $3,056,250 is payable.
- Registration Rights: Scilex must file registration statements for the resale of warrant shares. Failure to do so triggers liquidated damages of 2.0% per 30-day period, capped at 12.0% of the aggregate subscription amount.
- Beneficial Ownership Limitation: Warrants cannot be exercised if the Company would beneficially own more than 9.9% of Scilex Common Stock (unless notice is given to increase this limit).
- Collateral Priority: The Note is secured by a first-priority lien on all assets, except for specific permitted liens (e.g., an accounts receivable line of credit up to $30 million).
Investor Verification Checklist
- Verify the current status of Scilex's Chapter 11 bankruptcy proceedings and the finality of the "winning bidder" status.
- Confirm the exact principal balance of the Note after the $1,000,000 expense reimbursement capitalization.
- Review the vesting schedule and exercisability conditions of the "Subsequent Penny Warrants" (vesting dates: March, June, September, December 2024).
- Assess Scilex's ability to meet the mandatory prepayment triggers related to "Acceptable Indebtedness" and the 70% cash sweep provisions.
- Monitor the filing status of the Initial Registration Statement required under the Registration Rights Agreement to avoid liquidated damages.